Rx Enforcement In 2025: Shift Away From Opioid Makers But Tougher Approach On Ad/Promo

 
• By Sue Sutter

The compounding industry ties for Martin Makary, President-elect Trump’s candidate to lead the FDA, could mean less compounding enforcement, experts said, but government officials said their enforcement focus will remain nonpartisan.

2025 Pink Sheet Perspectives
DTC ads and compounded drugs could end up on opposite ends of the FDA enforcement pendulum. (Shutterstock)

More from Compliance

More from Manufacturing